Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Widschwendter

Showing results (171-180 of 175) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 175 results.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Nature Genetics|September 21, 2010
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Ellen L Goode, Georgia Chenevix-Trench, Honglin Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Pageof 18

Showing results (171-180 of 175) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 175 results.
JAMA Oncology|October 20, 2017
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer, Ellen L Goode, Matthew S Block, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2024
Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A M Saner, Kazuaki Takahashi, Timothy Budden, et al.
The Journal of Pathology. Clinical Research|March 22, 2023
p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium studyMartin Köbel, Eun-Young Kang, Ashley Weir, et al.
Nature Genetics|September 21, 2010
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24Ellen L Goode, Georgia Chenevix-Trench, Honglin Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)Aline Talhouk, Joshy George, Chen Wang, et al.
Pageof 18